Cabbacis to Host Live Webinar to Discuss $7.5 Million Offering and its Better Smoking and Vaping Alternatives

Hosting Live Webinar and Q&A for Potential Investors on Thursday, January 22, 2026, at 11:30 AM ET

NIAGARA FALLS, N.Y.–(BUSINESS WIRE)–$CABI #CABI–Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on its patented, iBlend™ harm-reduction products, today announced that as part of its $7.5 million Regulation A offering, the Company will host an Investor Webinar on Thursday, January 22, 2026 at 11:30 AM ET.

During the webinar, Joseph Pandolfino, CEO & Chairman of Cabbacis, will discuss the current opportunity to invest in the Company and the development and commercialization of its flagship iBlend™ cigarettes and vaporizer pods, which contain both very-low-nicotine tobacco and hemp. iBlend™ products are for assisting smokers or vapers to smoke or vape less, reduce nicotine exposure and dependence, and increase quit attempts. Investors will also learn about the Company’s leadership, FDA path to commercialize in the U.S., and international rollout expected later in 2026, to enable early revenue generation and brand validation ahead of U.S. entry.

Cabbacis Investor Webinar

Date: Thursday, January 22, 2026

Time: 11:30 AM ET

Register for the Webinar

Mr. Pandolfino stated, “We invite potential investors to join us to discuss our Regulation A offering to drive product development and advance the commercialization pathway of our iBlend™ cigarettes and vaporizer pods, which address the increasing demand for alternative tobacco products for reducing smoking, transitioning to less harmful products and/or quitting. This offering will further enable us to market our products and technology internationally.”

A replay of the webinar will be emailed to all registrants upon completion of the webinar; requests for a webinar replay copy can be made by contacting [email protected].

To learn more about the Regulation A offering or begin your investment, please visit us at www.cabbacis.com. Investors are not required to be accredited.

About Cabbacis

Cabbacis (OTCQB: CABI) is focused on commercializing groundbreaking, patented harm-reduction tobacco products for the world’s one billion smokers. Led by its flagship iBlend™ reduced-nicotine cigarettes and vaporizer pods in development, the Company is well positioned ahead of the proposed FDA rule to cap the nicotine content in all U.S. cigarettes. iBlend™ predominately contains tobacco combined with non-intoxicating hemp to assist in smoking or vaping less, transitioning to less harmful tobacco products, and/or increasing quit attempts. The Company also plans to commercialize reduced-nicotine tobacco cigarettes and little cigars without hemp and vaporizer pods with conventional-nicotine tobacco and hemp.

In a clinical trial reported by the Company, Cabbacis cigarettes were highly rated for satisfaction and significantly reduced cravings for usual brand cigarettes. Cabbacis holds a global patent portfolio of 35 issued patents and various pending patent applications – primarily covering tobacco-hemp combinations in cigarettes and vaporizer pods – across key markets including the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico and Brazil – where approximately two-thirds of the world’s smokers collectively reside.

To learn more, please visit cabbacis.com or follow us on LinkedIn or X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “foresee,” “intend,” “likely,” “may,” “objective,” “potential,” “plan,” “predict,” “project,” “seek,” “should,” “will” and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in “Risk Factors” in our Regulation A Offering Circular qualified by the SEC on November 24, 2025 and in our Annual Report on Form 1-K for the period ended December 31, 2024 filed with the SEC. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company’s securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of that state or jurisdiction.

Contacts

Investor Relations

Lucas A. Zimmerman

Managing Director

MZ Group – MZ North America

(949) 259-4987

[email protected]
www.mzgroup.us